O'Connor-Semmes RL - Search Results

1

Pharmacokinetics and ADME Characterization of Intravenous and Oral [¹⁴C]-Linerixibat in Healthy Male Volunteers.

Zamek-Gliszczynski MJ, Kenworthy D, Bershas DA, Sanghvi M, Pereira AI, Mudunuru J, Crossman L, Pirhalla JL, Thorpe KM, Dennison JMTJ, McLaughlin MM, Allinder M, Swift B, O'Connor-Semmes RL, Young GC. Zamek-Gliszczynski MJ, et al. Among authors: o connor semmes rl. Drug Metab Dispos. 2021 Dec;49(12):1109-1117. doi: 10.1124/dmd.121.000595. Epub 2021 Oct 8. Drug Metab Dispos. 2021. PMID: 34625435 Clinical Trial.

2

Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.

Sigafoos JF, Bowers GD, Castellino S, Culp AG, Wagner DS, Reese MJ, Humphreys JE, Hussey EK, O'Connor Semmes RL, Kapur A, Tao W, Dobbins RL, Polli JW. Sigafoos JF, et al. Among authors: o connor semmes rl. Drug Metab Dispos. 2012 Nov;40(11):2090-101. doi: 10.1124/dmd.112.047258. Epub 2012 Jul 30. Drug Metab Dispos. 2012. PMID: 22851617 Clinical Trial.

3

Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment.

O'Connor-Semmes R, Walker S, Kapur A, Hussey EK, Ye J, Wang-Smith L, Tao W, Dobbins RL, Cheatham B, Wilkison WO. O'Connor-Semmes R, et al. Drug Metab Dispos. 2015 Jul;43(7):1077-83. doi: 10.1124/dmd.114.062828. Epub 2015 May 1. Drug Metab Dispos. 2015. PMID: 25934577 Clinical Trial.

4

First-in-Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.

Cooper M, O'Connor-Semmes R, Reedy BA, Hacquoil K, Gorycki P, Pannullo K, Verticelli A, Shakib S. Cooper M, et al. Clin Pharmacol Drug Dev. 2019 Feb;8(2):234-245. doi: 10.1002/cpdd.600. Epub 2018 Sep 13. Clin Pharmacol Drug Dev. 2019. PMID: 30277655 Clinical Trial.

5

First-in-Human Study for a Selective Rearranged During Transfection Tyrosine Kinase Inhibitor, GSK3352589, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.

Reedy BA, O'Connor-Semmes R, Hacquoil K, Gorycki P, Verticelli A, Molga A. Reedy BA, et al. Clin Pharmacol Drug Dev. 2021 Apr;10(4):334-345. doi: 10.1002/cpdd.911. Epub 2021 Feb 19. Clin Pharmacol Drug Dev. 2021. PMID: 33606922 Clinical Trial.

6

Regional gastrointestinal delivery of remogliflozin etabonate in humans.

O'Connor-Semmes RL, Sandefer EP, Hussey EK, Tao W, Doll WJ, Page RC, Dobbins R. O'Connor-Semmes RL, et al. Biopharm Drug Dispos. 2013 Mar;34(2):79-86. doi: 10.1002/bdd.1824. Epub 2013 Jan 7. Biopharm Drug Dispos. 2013. PMID: 23111980 Clinical Trial.

7

Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus.

Hussey EK, Clark RV, Amin DM, Kipnes MS, O'Connor-Semmes RL, O'Driscoll EC, Leong J, Murray SC, Dobbins RL, Layko D, Nunez DJ. Hussey EK, et al. Among authors: o connor semmes rl. J Clin Pharmacol. 2010 Jun;50(6):623-35. doi: 10.1177/0091270009351879. Epub 2010 Jan 7. J Clin Pharmacol. 2010. PMID: 20056803 Clinical Trial.

8

GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects.

Lin J, Hodge RJ, O'Connor-Semmes RL, Nunez DJ. Lin J, et al. Among authors: o connor semmes rl. Diabetes Obes Metab. 2015 Oct;17(10):1007-10. doi: 10.1111/dom.12533. Epub 2015 Aug 11. Diabetes Obes Metab. 2015. PMID: 26179090 Clinical Trial.

9

Stereoselective pharmacokinetics of chlorpheniramine and the effect of ranitidine.

Koch KM, O'Connor-Semmes RL, Davis IM, Yin Y. Koch KM, et al. J Pharm Sci. 1998 Sep;87(9):1097-100. doi: 10.1021/js980045m. J Pharm Sci. 1998. PMID: 9724561 Clinical Trial.

10

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.

Hussey EK, Kapur A, O'Connor-Semmes R, Tao W, Rafferty B, Polli JW, James CD Jr, Dobbins RL. Hussey EK, et al. BMC Pharmacol Toxicol. 2013 Apr 30;14:25. doi: 10.1186/2050-6511-14-25. BMC Pharmacol Toxicol. 2013. PMID: 23631443 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page